Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety
CNS Neuroscience & Therapeutics · 2026-06 · 32 (6)
DOI: 10.1002/cns.70921 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 01.06.2026. Verfasst von Zhangyan Geng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Tacrolimus, Myasthenia Gravis, Immunosuppressive Agents, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Cohort Study of Myasthenia Gravis, National Key R&D Program of China, Precision Medicine Project.
Abstract (Originalsprache)
Aims
To identify factors influencing remission and relapse, and to evaluate the safety of tacrolimus monotherapy (TAMO) in adult‐onset mild‐to‐moderate myasthenia gravis (MG).
Methods
This retrospective analysis was conducted on MG patients receiving TAMO. Remission was defined as achieving minimal symptom expression (MSE), and multivariable Cox regression analysis identified predictors of remission and relapse. Cancer risk was assessed by standardized incidence ratio (SIR), based on the age‐specific cancer incidence rates in China in 2022.
Results
Among 153 patients, 77.8% achieved MSE, with a median time of 6.0 months. Age at onset (hazard ratio [HR] = 0.982, 95% confidence interval [CI] = 0.968–0.995, p = 0.009) and new‐onset MG (HR = 2.065, 95% CI = 1.266–3.368, p = 0.004) were independent predictors of time to achieving MSE. The optimal cut‐off value for age at onset was 70 years. Relapse occurred in 31% of patients. Tacrolimus concentration at MSE (HR = 0.815, 95% CI = 0.695–0.956, p = 0.012) and dose reduction speed (HR = 1.717, 95% CI = 1.280–2.305, p < 0.001) were independent predictors of relapse. The cut‐off values were 5.30 ng/mL and 1.08 mg/year, respectively. Adverse drug reactions (ADRs) occurred in 45.0% of the 200 patients receiving TAMO, with hyperglycemia being the most common (17.5%). Eight patients developed cancer, and the SIR was 2.86 (95% CI = 1.23–5.63, p = 0.005) compared with the general Chinese population.
Conclusion
TAMO was associated with higher rates of MSE in adult‐onset mild‐to‐moderate MG patients with new‐onset disease or with an onset age ≤ 70 years. To avoid MG relapse, tacrolimus concentration > 5.30 ng/mL at MSE and dose reduction speed ≤ 1.08 mg/year can be considered. Cancer surveillance may be considered for elderly patients undergoing long‐term tacrolimus therapy. Limitations include the retrospective, uncontrolled design, moderate sample sizes, and limited follow‐up duration; thus, long‐term safety, particularly cancer risk, requires further validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Zhangyan Geng, Nairong Xie, Yaye Wang, Qinyao Liu, Xinmei Wen
Förderung
- National Natural Science Foundation of China
- Clinical Cohort Study of Myasthenia Gravis, National Key R&D Program of China, Precision Medicine Project
Zitieren
APA
Geng, Z., Jiang, Y., Xie, N., Zhu, W., Chen, H., Wang, Y., Liu, H., Liu, Q., Lv, C., Qian, Y., Lu, Y., Di, L., Wang, M., Xu, M., Wen, X., Xie, B., & Da, Y. (2026). Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety. CNS Neuroscience & Therapeutics, 32(6). https://doi.org/10.1002/cns.70921
Vancouver
Geng Z, Jiang Y, Xie N, Zhu W, Chen H, Wang Y, et al. Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety. CNS Neuroscience & Therapeutics. 2026;32(6). doi:10.1002/cns.70921
BibTeX
@article{Geng2026,
author = {Geng, Zhangyan and Jiang, Yuting and Xie, Nairong and Zhu, Wenjia and Chen, Hai and Wang, Yaye and Liu, Haoran and Liu, Qinyao and Lv, Congwen and Qian, Yu and Lu, Yan and Di, Li and Wang, Min and Xu, Min and Wen, Xinmei and Xie, Bingchuan and Da, Yuwei},
title = {Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {6},
doi = {10.1002/cns.70921}
}
EUVIMED